Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - olmesartaanmedoksomiil+amlodipiin - õhukese polümeerikattega tablett - 20mg+5mg 14tk; 20mg+5mg 56tk; 20mg+5mg 100tk; 20mg+5mg 10tk; 20mg+5mg 28tk; 20mg+5mg 98tk

Eesti - eesti - Ravimiamet

zentiva k.s. - olmesartaanmedoksomiil+amlodipiin - õhukese polümeerikattega tablett - 20mg+5mg 30tk; 20mg+5mg 14tk; 20mg+5mg 98tk; 20mg+5mg 90tk; 20mg+5mg 56tk; 20mg+5mg 28tk

Eesti - eesti - Ravimiamet

accord healthcare b.v. - olmesartaanmedoksomiil+amlodipiin - õhukese polümeerikattega tablett - 40mg+10mg 30tk; 40mg+10mg 56tk; 40mg+10mg 500tk; 40mg+10mg 1000tk; 40mg+10mg 98tk; 40mg+10mg 28tk

Eesti - eesti - Ravimiamet

accord healthcare b.v. - olmesartaanmedoksomiil+amlodipiin - õhukese polümeerikattega tablett - 40mg+5mg 500tk; 40mg+5mg 56tk; 40mg+5mg 30tk; 40mg+5mg 98tk; 40mg+5mg 1000tk; 40mg+5mg 28tk; 40mg+5mg 90tk

Eesti - eesti - Ravimiamet

nordic pharma s.r.o. - sinekatehhiinid - salv - 100mg 1g 30g 1tk; 100mg 1g 15g 1tk

Eesti - eesti - Ravimiamet

accord healthcare b.v. - olmesartaanmedoksomiil+amlodipiin - õhukese polümeerikattega tablett - 20mg+5mg 98tk; 20mg+5mg 28tk; 20mg+5mg 30tk; 20mg+5mg 1000tk

Eesti - eesti - Ravimiamet

stiefel laboratories (ireland) ltd. - tõrv - šampoon - 1% 150ml 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

samsung bioepis nl b.v. - bevatsizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastilised ained - aybintio in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. aybintio in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. lisateavet inimese epidermaalse kasvufaktori retseptori 2 (her2) seisundi kohta vt palun 5. jaotisest. 1 of the smpc. aybintio in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracyclinecontaining regimens in the adjuvant setting within the last 12 months should be excluded from treatment with aybintio in combination with capecitabine. her2 staatuse kohta lisateabe saamiseks lugege palun 5. jaotist. 1 of the smpc. aybintio, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. aybintio, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. 1 of the smpc). aybintio in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. aybintio, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. 1 of the smpc). aybintio, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. aybintio, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. 1 of the smpc). aybintio, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5. 1 of the smpc).

Euroopa Liit - eesti - EMA (European Medicines Agency)

centus biotherapeutics europe limited - bevatsizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell - antineoplastilised ained - bevatsizumab kombinatsioonis fluoropürimidiinil põhineva kemoteraapiaga on näidustatud käärsoole või pärasoole metastaatilise kartsinoomi raviks täiskasvanud patsientidel. bevacizumab koos paclitaxel on näidustatud esimese rea raviks täiskasvanud patsientidel metastaatilise rinnavähi. lisateavet inimese epidermaalse kasvufaktori retseptori 2 (her2) seisundi kohta vt palun 5. jaotisest. bevacizumab koos capecitabine on näidustatud esimese rea raviks täiskasvanud patsientidel metastaatilise rinnavähi, kelle ravi teiste keemiaravi võimalusi, sealhulgas taxanes või anthracyclines ei ole asjakohane. patients who have received taxane and anthracycline- containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with equidacent in combination with capecitabine. her2 staatuse kohta lisateabe saamiseks lugege palun 5. jaotist. bevacizumab, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. bevacizumab, koos erlotiniibi, on näidustatud esimese rea raviks täiskasvanud patsientidel, kellel unresectable kaugelearenenud, metastaatilise või korduv mitte-soomusrakuline non-small cell lung cancer, mille epidermaalse kasvufaktori retseptori (egfr) aktiveerivad mutatsioonid. bevacizumab in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer. bevacizumab, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iiib, iiic and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. bevacizumab, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor-targeted agents. bevacizumab, koos paclitaxel ja cisplatin või, teise võimalusena, paclitaxel ja topotecan patsientidel, kes ei saa platinum ravi, on näidustatud ravi täiskasvanud patsientidel, kellel on püsivad, korduvad, või metastaatilise kartsinoomi, emakakaela.

Euroopa Liit - eesti - EMA (European Medicines Agency)

samsung bioepis nl b.v. - bevatsizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastilised ained - onbevzi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. onbevzi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. lisateavet inimese epidermaalse kasvufaktori retseptori 2 (her2) seisundi kohta vt palun 5. jaotisest. onbevzi in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with onbevzi in combination with capecitabine. her2 staatuse kohta lisateabe saamiseks lugege palun 5. jaotist. onbevzi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. onbevzi, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. onbevzi in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. onbevzi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. onbevzi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. onbevzi, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. onbevzi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.